DARA + VRd in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Analysis of Minimal Residual Disease in the PERSEUS Trial

Cesar Rodriguez, MD, and Frits van Rhee, MD, PhD, discuss the overall frontline treatment landscape for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM).

Hematologic oncology specialists provide an overview of the study design of the PERSEUS trial and outline the role of MRD negativity in the treatment of patients with multiple myeloma.

Myeloma specialists provide comprehensive insights on key data from the PERSEUS trial evaluating MRD status in patients receiving DARA-VRd and VRd.

Experts on multiple myeloma discuss the safety profile of DARA-VRd in patients with newly diagnosed multiple myeloma.

Frits van Rhee, MD, PhD, and Cesar Rodriguez, MD, provide key takeaways on findings from the PERSEUS trial and discuss unmet needs that remain in the multiple myeloma treatment landscape.

Minimal residual disease as an end point in multiple myeloma has been widely discussed and was even a topic of a recent ODAC meeting.